Related Experiment Videos
Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomized, cross-over study
J J Heimans1, B Drukarch, I Matthaei
1Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
Acta Neurologica Scandinavica
|December 1, 1991
Summary
Cyclandelate did not improve nerve function or pain in diabetic neuropathy patients. This study found no evidence that the drug is effective for treating this condition.
Area of Science:
- Neurology
- Pharmacology
- Diabetology
Background:
- Cyclandelate may improve blood flow and has shown promise in prior diabetic neuropathy studies.
- Diabetic neuropathy affects peripheral nerves, causing sensory and motor deficits.
- Improving rheological properties is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of cyclandelate in treating diabetic neuropathy.
- To assess cyclandelate's impact on nerve conduction and sensory perception.
- To determine if cyclandelate reduces pain in diabetic neuropathy patients.
Main Methods:
- A double-blind, placebo-controlled, cross-over study design was employed.
- 40 diabetic patients with neuropathy received cyclandelate (1600 mg daily) or placebo.
- Nerve conduction velocities, late responses, thermal and vibration thresholds, and pain were measured.
Main Results:
- No significant improvements were observed in motor or sensory nerve conduction.
- Late responses, thermal discrimination, and vibration perception thresholds showed no change.
- Pain scores in patients treated with cyclandelate did not decrease.
Conclusions:
- Cyclandelate demonstrated no beneficial effect in the treatment of diabetic neuropathy.
- The drug's potential to improve peripheral nerve blood supply was not confirmed in this study.
- Further research may be needed to explore alternative treatments for diabetic neuropathy.